Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
about
Defining and Measuring the Affordability of New Medicines: A Systematic Review.Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaEfficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseAffordability of medicines in the European UnionIntroduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureCost-effectiveness thresholds: pros and cons.Risk behaviour determinants among people who inject drugs in Stockholm, Sweden over a 10-year period, from 2002 to 2012.Shortening the duration of therapy for chronic hepatitis C infection.On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study.Is elimination of hepatitis C from the UK by 2030 a realistic goal?Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA.Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment.Therapeutic Approaches for Zika Virus Infection of the Nervous System.Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?Pathways to the elimination of hepatitis C: prioritising access for all.When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia.The cost and value of cancer drugs - are new innovations outpacing our ability to pay?A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change.Hepatitis C in haemophilia: time for treatment for all.Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines.Economic evaluation of HCV testing approaches in low and middle income countries.Can Price Transparency Contribute to More Affordable Patient Access to Medicines?Strategic procurement and international collaboration to improve access to medicines.Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015.Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.Value-Based Pricing: L'Enfant Terrible?Research gaps in viral hepatitis.Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?Approaches to manage 'affordability' of high budget impact medicines in key EU countries.
P2860
Q30234551-B5213B44-40D9-441D-BA85-DF133F527B9BQ33698956-20AF54E0-2700-4095-BB6D-8EF62A889E11Q36240269-A53042ED-4013-4715-AC73-0F6567ECA286Q36291455-6DBC0966-41AF-4801-9AD1-759A0D4C445BQ37135584-291EABAB-73CF-4B4F-8228-D9294D390B29Q37498173-8EDEF71D-836D-47FA-819D-7B9F467E8AE7Q38372109-047506A5-9FEB-40C2-AAA9-1AF5CF0F140AQ38627508-C91F4BE5-C0AB-4B15-88EF-926B31BF201DQ38661388-E1DFC07C-CFB3-466D-943B-A8C80C385974Q38729888-B90F39F2-442D-4C8C-9291-B76F5D271575Q38748387-DA7CECE1-5E72-4581-902D-93591AF875B7Q38758403-357266DA-B5DF-4C11-B54C-94604385FB7BQ38858834-2F4D84FE-B603-4578-B3F8-3B6CF5F6B025Q39072439-4D0E8B16-D290-45F5-937B-FC24699874D5Q40042851-43805D3D-EB1B-4238-AF05-3D26FA0EA098Q40072613-7C397139-47C8-496E-8EB5-A23E8595CFE6Q40109414-B6D45428-98BB-45ED-8178-BD1458CCB94DQ40129813-3880A372-2A7D-4E35-A820-2960B4AE63B3Q40301168-91C421C6-CBA0-4154-94FA-0AFC050BEFC1Q41918254-028035DF-D647-4530-976A-A004DE6CA647Q41925862-E1C71923-CA35-4E24-A104-4F9A2967A682Q41931180-3C6C2BFD-CB07-4E91-92E1-D5CB61A59B2DQ42368917-7A04B0BA-E284-4B37-A333-55C70B77A73BQ42373161-C7DE2DEF-9D90-4DA6-BCE7-88A4BC5021D1Q42392412-E30282ED-31CE-493D-B8C9-C9DE0E0E3018Q42700925-AE7F1C5D-91B3-4EEF-B8E2-204F779ED2D5Q44697952-CFA65791-6EE2-4604-AD95-B5105771D096Q45865711-82AF74B4-A0FC-49CC-A26D-EDEFB49669E0Q46707957-61AFC06F-A1BF-4361-BD21-5001C732F18FQ46983780-6F0A9D54-5C8C-4B26-B37D-5A188F37CFC9Q47099148-451CC59E-3354-46C5-843B-C74C576E7AD1Q47262256-2AB0541C-A8B7-4B4A-8B5C-1802747D05B5Q47274730-E2F27C2B-527C-44DD-97D1-8CF9CDB4105BQ47548368-35B01E09-BADF-4C94-8E6B-9A34D147D87BQ47569013-9875E118-52FD-41F0-A503-3C6CC8CFA2E8Q47573504-F27189A4-D686-4F45-A301-E556EB50C4BEQ49756124-972D25DA-A802-4BEF-BE00-1AC918BF75A7Q52597010-C4FE67AD-4D90-4EB2-B3AB-12E1E59FB8B6Q52597017-6CEEC346-0CB4-4C9D-80FD-D7FF8177341CQ55171710-33B5CC54-220E-4348-902C-CE7AF0B17871
P2860
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@ast
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@en
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@nl
type
label
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@ast
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@en
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@nl
prefLabel
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@ast
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@en
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@nl
P2093
P2860
P3181
P1433
P1476
Prices, Costs, and Affordabili ...... ountries: An Economic Analysis
@en
P2093
Kees de Joncheere
Kiu Tay-Teo
Peter Beyer
Sabine Vogler
Stefan Wiktor
Suzanne Hill
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1002032
P407
P577
2016-05-01T00:00:00Z